Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells

Patent metadata

Field	Value
Publication number	US-10961587-B2
Application number	US-201515507668-A
Country	US
Kind code	B2
Filing date	Aug 28, 2015
Priority date	Aug 28, 2014
Publication date	Mar 30, 2021
Grant date	Mar 30, 2021

Abstract

In certain embodiments, this application discloses methods for detecting lung cancer. The method includes characterization of cells extracted from human sputum, which is a valuable tissue surrogate and source of upper respiratory cells that become cancerous early in 5 the process of lung cancer development. The method includes the staining of extracted cells with fluorescent reporters that produce a specific pattern in the nuclei of labeled cells, which can be made visible by light microscopy. The pattern is relevant to a type of epigenetic coding of DNA known as DNA methylation, which changes in specific cells of the lung during cancer development, in comparison to normal respiratory cells.

First claim

What is claimed is:

1. A method for measuring the existence of a cancerous or precancerous cell in a patient, the method comprising:
receiving an image data output from a scanning device, wherein the image data output comprises images of a set of cells that are identified by a cytoplasmic label;
processing the image data output to select a first set of images of epithelial cells for further analysis;
delineating nuclei of the epithelial cells in the first set of images;
measuring a signal intensity of global 5-methylcytosine (5mC) content and a signal intensity of global DNA (gDNA) content in a nucleus of each of the epithelial cells in the first set of images;
generating a 3D colocalization pattern from the signal intensity of the global 5mC content and the signal intensity of the gDNA content;
creating a 2D scatterplot of the 3D colocalization pattern, wherein (a) each point in the 2D scatterplot comprises a voxel of each nucleus, (b) an angle of a regression line of the 2D scatterplot represents a global 5mC/gDNA colocalization value, and (c) the slope of the angle corresponds to the global 5mC content;
determining that the angle for the measured cell is equal to or less than 20 degrees;
based at least in part on determining that the angle for the measured cell is equal to or less than 20 degrees, identifying the measured cell inside the patient as a cancerous cell or a precancerous cell; and
in response to identifying the measured cell inside the patient as a cancerous cell or a precancerous cell, treating the patient by (i) administering chemotherapy, (ii) administering radiation therapy, (iii) performing surgery, or (iv) any combination thereof.

2. The method of claim 1 , wherein the set of cells were obtained from a biological sample.

3. The method of claim 2 , wherein the biological sample comprises sputum.

4. The method of claim 3 , wherein the sputum comprises respiratory cells.

5. The method of claim 2 , wherein the biological sample is lung tissue.

6. The method of claim 2 , wherein the biological sample was obtained from a subject who is a smoker.

7. The method of claim 2 , wherein the biological sample was obtained from a subject who is not a smoker.

8. The method of claim 2 , wherein the biological sample was obtained from a subject who has lung cancer and has not been treated for lung cancer.

9. The method of claim 2 , wherein the biological sample was obtained from a subject who has received a lung cancer treatment selected from the group consisting of:
radiation therapy, chemotherapy, surgery, and combinations thereof.

10. The method of claim 1 , wherein the global 5mC and gDNA contents were measured with a microscope after the cells have been subjected to (a) immunofluorescence staining with an antibody specific for the global 5mC, and (b) counterstaining with 4′,6-diamidino-2-phenylindole (DAPI).

11. The method of claim 4 , wherein the sputum sample was obtained from a subject by a method comprising:
administering hypertonic saline into the subject's respiratory tract; and
collecting a quantity of sputum that is expelled from the subject as the result of inhaling said hypertonic saline.

12. The method of claim 11 , wherein the hypertonic saline is administered via a nebulizer.

13. The method of claim 11 , wherein the hypertonic saline is 3-5% NaCl.

14. The method of claim 1 , wherein the step of identifying a measured cell inside the patient as a cancerous cell or a precancerous cell further comprises determining that the global 5mC content of the measured cell is 25% or less than the global 5mC content found in a non-cancerous cell.

15. The method of claim 1 , wherein the image data output further comprises: (a) a lateral resolution in a range of 100-200 nm that is represented in x and y-axis and (b) a vertical resolution of about 500 nm that is represented in z-axis.

16. The method of claim 1 , wherein the scanning device is a confocal scanning microscope.

17. The method of claim 1 , further comprising enumerating the identified cancerous cell or precancerous cell, wherein the treating the patient is in response to determining that the enumeration exceeds a predetermined threshold.

18. The method of claim 17 , wherein the predetermined threshold is a majority of the epithelial cells in the first set of images.

19. The method of claim 1 , wherein the identifying the measured cell inside the patient as a cancerous cell or a precancerous cell is further based at least in part on the global 5-methylcytosine (5mC) content, the 5mC/gDNA colocalization value, or both.

Assignees

• Cedars Sinai Medical Center
• Univ California
• Us Gov Represented By The Department Of Veterans Affairs
• Us Govt Dept Of Veterans Affairs

Inventors

• Tajbakhsh Jian
• Mortazavi Fariborz

Classifications

• G01N33/5752 Primary

  of the lungs · CPC title

• C12Q1/6841

  In situ hybridisation · CPC title

• G01N1/30

  Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis} · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N2440/12

  alkylation, e.g. methylation, (iso-)prenylation, farnesylation · CPC title